**Table S2:** *In Vitro* Antiviral Activity of PF-3759857 Against Different HIV-1 Clinical Isolates or Laboratory Strains in PBMCs[a]. Supplementary to Figure 1, the properties of the various isolates tested (represented by single points) against the compound are shown.

| HIV-1 Isolate | Clade[b] | Receptor | $EC_{50}$ (μM) | TI[c] |
|---|---|---|---|---|
| IIIB | B | X4 | 1.36 | >73.7 |
| JR-CSF | B | R5 | 1.19 | >84.0 |
| 92BR014 | B | R5/X4 | 3.17 | >31.5 |
| 92BR021 | B | R5 | 1.25 | >80.0 |
| 92BR025 | C | R5 | 1.08 | >92.4 |
| 92BR020 | B | R5 | 1.55 | >64.7 |
| 92RW016 | A | R5 | 1.14 | >87.9 |
| 92TH014 | B | R5 | 1.34 | >74.6 |
| 92TH026 | B | R5 | 1.94 | >51.4 |
| 93BR017 | B | R5 | 1.62 | >61.9 |
| 93BR020 | F | R5/X4 | 1.03 | >97.1 |
| 93BR021 | B | R5 | 0.60 | >166 |
| 93BR023 | B | R5 | 0.77 | >130 |
| 96USHIPS7 | B | R5 | 1.03 | >97.1 |
| 91US056 | B | R5 | 1.76 | >56.8 |
| 92US076 | B | R5 | 1.03 | >96.8 |
| 98IN017 | C | X4 | 0.51 | >196 |
| 93IN101 | C | R5 | 1.01 | >99.3 |

[a]Antiviral activity was determined by measuring RT activity 7 days after infection of PBMCs with HIV-1 clinical isolates. (X4, CXCR4; R5, CCR5).

[b]Clade and receptor assignments based on designations from the NIH AIDS Research and Reference Reagent Program or our collaborator for the study (SRI).

[c]TI, therapeutic index calculated by dividing the mean $EC_{50}$ value into the mean $CC_{50}$ value determined in PBMCs (>100 microM).